(r)-propafenone

Small moleculeexperimental

Clinical trial activity

3 trials · 8 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
2
Phase 3
1
Phase 4
0

Earliest trial started Oct 1, 2016 (NCT02710669)

Timeline

2010s

  1. Jan 1, 2016

    Earliest Phase 1 Sponsor(trial)

2020s

  1. Jan 1, 2023

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

  • Unspecified targetUnclear

    Unclear

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Also known as

  • (r)-propafenone
  • (r)-propafenone

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06096337N/ADec 15, 2023Boston Scientific Corporation, The Cleveland Clinic
NCT05939076Phase 3Aug 21, 2023Orebro University, Swedish Heart Lung Foundation, The Swedish Research Council, Uppsala University
NCT02710669Phase 1/Phase 2 (Phase 2)Oct 1, 2016National Heart, Lung, and Blood Institute (NHLBI), Vanderbilt University
Showing 3 of 3 trials
Page 1 / 1

Organizations

Research & Development (8)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Boston Scientific CorporationFor profit1112023
National Heart, Lung, and Blood Institute (NHLBI)Government1012016
Orebro UniversityAcademic/Hospital1112023
Swedish Heart Lung FoundationAcademic/Hospital1012023
The Cleveland ClinicAcademic/Hospital1012023
The Swedish Research CouncilAcademic/Hospital1012023
Uppsala UniversityAcademic/Hospital1012023
Vanderbilt UniversityAcademic/Hospital1112016
8 organizations
Page 1 / 1